Breaking News

Oil Falls to $90 a Barrel for First Time in 17 Months
Tweet TWEET

Alere to Launch "Test Target Treat™" Campaign at 9th Annual International Symposium on Antimicrobial Agents and Resistance

  Alere to Launch "Test Target Treat™" Campaign at 9th Annual International
               Symposium on Antimicrobial Agents and Resistance

Company Responds to Call from World Economic Forum Describing Antimicrobial
Resistance as Greatest Threat to Global Health

PR Newswire

WALTHAM, Mass., March 13, 2013

WALTHAM, Mass., March 13, 2013 /PRNewswire/ --Alere Inc. (NYSE: ALR) is
pleased to announce the launch today of a new campaign, Test Target Treat™, at
the 9^th Annual International Symposium on Antimicrobial Agents and
Resistance. The campaign is designed to combat antimicrobial resistance by
educating healthcare professionals on the importance of using rapid
diagnostics to make more targeted treatment decisions and reduce the
inappropriate use of antibiotics.

Antimicrobial resistance (AMR) occurs when microorganisms mutate or acquire
resistance genes that enable them to withstand previously effective
antimicrobial treatments. It is generally a consequence of the misuse of
antibiotics, a rapidly growing global public health concern. In fact, in its
2013 Global Risks Report, the World Economic Forum identified antimicrobial
resistance as the greatest threat to human health today and called for
incentives to prevent the over-prescription of antibiotics.

"Until now, new antibiotics have been developed to replace older, increasingly
ineffective ones. However, human innovation may no longer be outpacing
bacterial mutation," stated the report. "[We must find] new ways to stimulate
the development of new antibiotics as well as align incentives to prevent
their overuse."

The Test Target Treat™ campaign is intended to reinforce the fact that
antibiotics are over-prescribed in 50% of all cases and that treating viral
infections with antimicrobial therapies is counterproductive to achieving
broad global health. Alere offers a best-in-class rapid diagnostic, the Alere
Afinion^TM CRP Test, which enables healthcare practitioners to distinguish
between respiratory tract infections that require treatment and those that are
self-limiting. The company also provides several other diagnostic tools that
can help clinicians identify pathogens at the point of care and define an
appropriate treatment strategy earlier. These include solutions for Strep A,
RSV, Influenza, S. pneumoniae, MRSA and C. difficile. By supplying healthcare
providers with a comprehensive set of diagnostic information, Alere hopes to
initiate a shift in treatment trends, moving away from the broad
over-prescription of antibiotics, which spawned the growing prevalence of
serious healthcare-associated infections like MRSA, towards more targeted
therapy.

To learn more about Alere's Test Target Treat^TM campaign and industry-leading
diagnostics, please visit booths #23 and 24. More information is also
available on the campaign's website: www.TestTargetTreat.com.

About Alere
By developing new capabilities in near-patient diagnosis, monitoring and
health information technology, Alere enables individuals to take charge of
improving their health and quality of life at home. Alere's global leading
products and services, as well as its new product development efforts, focus
on cardiology, infectious disease, toxicology and diabetes. Alere is
headquartered in Waltham, Massachusetts. For more information regarding
Alere, please visit www.alere.com.

SOURCE Alere Inc.

Website: http://www.alere.com
Contact: Eric Hartsock, +1-443-858-4437
 
Press spacebar to pause and continue. Press esc to stop.